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The Retinoblastoma (Rb) gene was the first tumor suppressor discovered.  In 
many, if not all, human tumors Rb is functionally inactivated.  In a normal cell, the Rb 
protein is a transcription regulator that controls the cell cycle, differentiation, and cell 
death.  Studies have shown that mice carrying one Rb mutant allele (Rb+/-) are highly 
cancer prone and do not live as long as wild type mice.  Furthermore, completely Rb 
deficient embryos (Rb-/-) die in mid-gestation around the 14th embryonic day (E14) of 
development.  Analysis of Rb-/- embryos reveals defects in hematopoiesis, neurogenesis, 
and lens fiber development.  At least in part, these defects arise from the inappropriate 
regulation of the cell cycle.  Studies of Rb function have led to the discovery of the E2F 
transcription family.  The E2F family of transcription factors are downstream targets of 
Rb and work with Rb in controlling the cell.  Numerous studies indicate that the E2F 
family of transcription factors regulates expression of genes that are important for cellular 
proliferation.   
To date, eight E2F family members have been identified.  E2F3 is unique in that it 
has been demonstrated to play a role in the G1/S phase transition.  Recently the gene 
locus for E2f3 was found to encode two distinct mRNAs, E2f3a and E2f3b.  They share 
homology throughout the protein sequence from exon 2 to the C-terminus.  Both proteins 
share the same nuclear localization signal, DNA binding, heterodimerization, and pocket 
protein binding domains; however, E2F3a has an additional cyclin A binding domain.  
Furthermore, E2F3b is expressed constitutively in quiescent cells, but E2F3a is tightly 
regulated and present in proliferating cells.  Unlike E2F3, mice lacking E2F3a are healthy 
and show no other signs of reduced viability or livelihood.     
E2F3a being a downstream target of Rb suggests that its loss could mitigate the 
Rb-/- phenotype.  To test this hypothesis an in vivo approach was used to generate E2F3a-
/-; Rb-/- double mutant embryos.  The embryos were harvested at E13.5 at which point 
cells from the placenta, blood, central nervous system, peripheral nervous system, and 
lens were examined.  BrdU incorporation was used to distinguish proliferation and 
TUNEL assays were used to detect apoptosis.  Also, H & E staining was used to examine 
overall morphology of the different tissue types.  As predicted by the hypothesis, the lack 
of E2F3a completely compensated for the loss of Rb in the placenta and central nervous 
system.  In the peripheral nervous system and the lens the loss of E2F3a partially rescued 
the Rb-/- phenotype, but the red blood cells showed no rescue in the reduction of 
nucleated cells.  Interestingly, the E2F3a-/-; Rb-/- embryos survived up to E17.5.  More 
experiments are being done to assess whether the lack of E2F3a increases the lifespan of 
Rb+/- mice that are cancer prone.   
Elucidating the specific functions of the E2F family members is critical to 
understanding the intricacies of cell cycle regulation, tumorigenesis, and differentiation.  
Working to completely comprehend the interaction between E2F3a and Rb during 
development could lead to new insight into understanding cancer. 
Introduction  
Over twenty years ago the Retinoblastoma (Rb) gene was identified as the first 
tumor suppressor1.  Mutations in the Retinoblastoma gene were originally implicated in a 
childhood eye cancer2.  Although rare, the retinoblastoma disease is a malignant 
neoplasm that originally affects the eyes of children usually under the age of three3.  With 
proper treatment and baring metastasis, retinoblastoma is usually not lethal3.   Studying 
the disease showed the Rb is required for proper lens development3.  Interestingly, the 
loss of Rb affected different tissues differently.  Lack of Rb in the eye will lead to cancer; 
whereas, other tissues show no abnormal phenotype in the absence of Rb4.  Continuous 
research has greatly expanded the Rb paradigm and emphasized the importance of Rb.  In 
fact, early studies of the gene have unveiled that cancer can result if Rb function is 
derailed3.  Most researchers agree that Rb is mutated in most, if not all, human cancers1.   
The Rb protein is a large nuclear transcription factor.  It is 928 amino acids long 
and has multiple binding sites for different targets such as HDAC1 and the E2Fs5,6.  
Earlier studies have unearthed Rb as a cornerstone of the cell cycle3.  It functions as a 
regulator of transcription that controls the cell cycle, proliferation, and apoptosis7.  Rb is 
regulated through the cell cycle by phosphorylation at multiple serine and threonine 
sites8.  G1 and the initiation of replication are controlled by this phosphorylation 
mechanism.  If Rb remains hypophosphorylated then target proteins remain bound and 
the cell is arrested in G18.  Continued phosphorylation of Rb by G1 cyclin-dependent 
kinases (Cdks), primarily D-type cyclins and Cdk 4, results in cell cycle progression8. 
Because of the crucial role of Rb in the cell cycle, numerous studies have been 
conducted to further elucidate the role of Rb.  These studies have shown that the loss of 
Rb has deleterious effects on cells.  Mice that lack one copy of Rb (Rb+/-) are highly 
cancer prone9.  Cancer primarily arises in the pituitary gland with high levels of 
metastasis and reduces the viability of these mice to around 10.5 months9.  These results 
prove the important role of Rb in cancer.  Furthermore, the appearance of pituitary 
tumors instead of ocular tumors indicates different phenotypes of Rb-induced tumors.  
The complete inactivation of Rb results in unscheduled cell proliferation, apoptosis and 
developmental defects10.  Furthermore, mice that completely lack Rb die in midgestation 
around embryonic day fourteen (E14)11.  Analysis of Rb-/- embryos reveals defects in 
hematopoiesis, neurogenesis, and lens development7.  At least in part, these defects arise 
from ectopic S-phase entry and apoptosis caused by the loss of Rb.  At E13.5 the 
phenotypic consequences of Rb-deficiency are most apparent12.  At this time, ectopic 
proliferation and high levels of apoptosis are not only found in the aforementioned 
tissues, but also in the placenta13.  The irregular cell cycle causes dysplasia of trophoblast 
cells in the labyrinth of the placenta13.  Oxygen and nutrient exchange between the 
embryo and mother occurs at the labyrinth, so irregularities in this tissue are 
detrimental13. 
Two models have been suggested for the lethality of embryos at midgestation.  
First, some scientists claim that Rb-deficient embryos die of anemia due to abnormal red 
blood cells (RBCs)7.  In Rb-deficient mice blood cells remain nucleated, which deprives 
the cell of the ability to carry oxygen.  Through normal embryonic development RBCs 
lose their nucleus during differentiation.  The second model, proposed by Wu et al., 
suggests that Rb-deficient mice die during midgestation because of defects in the 
placenta13.  In their experiment they replaced the placenta of an Rb-deficient embryo with 
a wild-type placenta.  This placenta replacement rescued the placenta phenotype and 
other phenotypes affected by Rb-deficiency except the lens tissue. Also, RBCs remained 
nucleated13.  Surprisingly, the Rb-deficient embryos with wild-type placentas had 
extended viabilities instead of dying at E1413.  A few embryos survived to full-term, 
though died shortly after birth.  Their experiments showed that the viability of an embryo 
depends on the normal function of the placenta.   
Through various experiments, the role of Rb in embryonic development is being 
elucidated.  Apparently Rb is needed at two separate times during embryonic 
development7.  First, Rb functions during midgestation to restrict transcription activators 
such as E2F7.  This regulates the cell cycle and ensures normal proliferation.  Later in 
development Rb directs the development of certain tissues.  In Wu’s study the Rb-
deficient embryos with wild-type placentas had extended viabilities, but had other 
developmental defects in tissues due to the lack of Rb13.   
The ever increasing knowledge of Rb has led to the discovery of new proteins and 
new pathways related to the newly discovered proteins.  The discovery of the E2F 
transcription family are a result of studying Rb14.  The E2F family of transcription factors 
is downstream targets of the Rb tumor suppressor and work with Rb in controlling the 
cell cycle. Currently, eight E2F genes have been discovered as well as two DRTF 
proteins (DPs).  Although the E2Fs heterodimerize to a DP to form a functional complex, 
the E2F protein dictates the function of the dimerized protein15.  Based on transcription 
activity the E2Fs can be broken down into two groups16.  E2F1, E2F2, and E2F3 are 
considered to be transcription activators and they bind exclusively to Rb.  The activator 
E2Fs are transcription factors for genes that are required for DNA replication and cell 
cycle regulation1.  They bind at the promoters for genes such as Orc1, cdc6, cyclin E, and 
Mcm1.  The activator E2Fs are tightly regulated during the cell cycle1.  Their activities 
spike at the end of G1 while they are not expressed nor have low activity in quiescent 
cells.  On the other hand, E2F4, E2F5, E2F6, E2F7 and E2F8 are transcription repressors.  
E2F4 has the ability to bind to Rb as well as to Rb-related proteins, p107 and p13038.  
E2F5 can only bind to p13017.  The E2F6 protein does not bind to any Rb family 
member at all; it only associates with the mammalian polycomb complex17.  E2F4 and 
E2F5 derive their repressor ability by occupying the promoters of E2F-responsive genes 
after complexing with an Rb family member and histone deacetylase17.  Not much is 
known about the mechanism of E2f6, but recent evidence suggests that it is a repressor17. 
E2f7 and E2f8 were only recently discovered and there is not much information 
regarding their activity as of yet except that they are repressors. 
The Rb/E2F pathway (fig. 1) is the cornerstone for the cell cycle by being 
responsible for initiating the G1/S-phase transition.  Rb blocks transcription by two 
different mechanisms.  Rb is able to bind the E2F activating transcription factors, which 
inactivates their ability to turn on downstream genes responsible for proliferation8.  Rb 
also associates with the repressor E2Fs and histone deacetylases at the E2F promoter 
target sites; this complex represses transcription via negative regulation.  As mentioned 
earlier, Rb is regulated by phosphorylation.  Upon mitogen stimulation, G1 Cdks, 
primarily D-type cyclins and Cdk 4, phosphorylate specific sites on the Rb protein.  If Rb 
is hypophosphorylated then the E2Fs are able to bind to the protein.  Rb must be 
phosphorylated at different sites, mainly in the C-terminus region, to cause a 
conformational change which causes the bound protein to dissociate.  One model claims 
that the phosphorylation of Ser-567 is the ultimate phosphorylation event to cause the 
E2F to dissociate and not be able to bind anymore18.  This phosphorylation disrupts the 
A-B pocket of Rb and changes the protein shape, which will not bind E2F anymore18.  
Once activator E2Fs are released they are able to activate transcription by binding to the 
promoters of genes that are required for S-phase. 
Many studies have been conducted by altering this pathway by knocking out 
certain proteins or over expressing others.  Through these studies Rb and the activator 
E2Fs have been found to have opposing roles.  Activator E2Fs serve to promote 
transcription; whereas, Rb binds to E2Fs to repress transcription.  In these experiments 
many different defects have been observed.  Mice that lack E2F3 have severe 
developmental defects and die early of congestive heart failure and Rb+/- mice are highly 
cancer prone16,2.  By combining these genotypes (Rb+/-; E2f3-/-) the phenotypes were 
ameliorated.  The mice lacked the developmental defects associated with loss of E2F3 
and exhibited tumor suppression14.  MEFs that have all three activator E2Fs knocked out 
(E2f1-/-; E2f2-/-; E2f3-/-) are arrested in G17.  However, if all activator E2Fs are over 
expressed then the MEFs undergo ectopic S-phase entry7.  Tumor prone Rb+/- mice that 
lack E2F1 have extended viability; however, there is not a complete rescue to the wild 
type phenotype14.  Studying the numerous E2Fs have exposed the incredible complexity 
of the family.  Some scientists believe that the activator E2Fs have overlapping or 
redundant functions16.  For instance, in MEFs that lack E2F3 the over expression of E2F1 
rescues the delay in proliferation found in E2f3-/- MEFs19.  Contrary to this belief, there is 
evidence that each E2F serves a specific function.  Such as E2F3 serves as a transcription 
factor at the p19ARF promoter20.  In mice that lack E2F3 p19ARF is over expressed.  
There is no redundancy between the E2Fs to regulate the expression of p19ARF20.  The 
duality of redundancy and unique properties of the E2Fs further enhance the complexity 
of the Rb-E2F pathway. 
Other complex mechanisms of the Rb/E2F pathway have been discovered to 
regulate apoptosis.  The loss of Rb triggers p53-dependent apoptosis8.  Other scientists 
have found that cells limit growth potential by regulating phosphorylation at Ser-567.  
Cells that are phosphorylated at the Ser-567 residue are more susceptible to apoptosis58.  
E2Fs can induce apoptosis too.  Free E2Fs can activate both p53-dependent and p53-
independent apoptosis18.  Whether apoptosis in Rb-deficient cells is caused by the loss of 
Rb or free E2Fs is not currently understood.  Given the facts that activating E2Fs can 
promote proliferation and also promote apoptosis makes them interesting.  Activator 
E2Fs act as both an oncogene and a tumor suppressor.  At low concentrations they act as 
an oncogene, but at a high concentration they promote apoptosis and act as a tumor 
suppressor14. 
Probably the most interesting member of the E2F family is E2F3.  E2F3 plays a 
key role in the activation of most E2F responsive genes19.  Depending on modifiers in 
strain backgrounds, E2F3 is critical for full neonatal viability7.  E2f3-/- that survive birth 
die early of congestive heart failure resulting from atrial thrombus formation and 
pulmonary edema16.  If combined with the loss of E2F1 also, the mice always die before 
birth16.  As mentioned earlier the loss of E2F3 in Rb+/- mice suppresses pituitary gland 
tumors, its loss increases the frequency of tumors in the thyroid gland14.  This suggests 
that E2F3 may have tissue-specific functions.  Without E2F3, cells do not proliferate 
sufficiently; MEFs take twice as long to proliferate19.  However, no apoptosis defect is 
noticeable19.  Surprisingly, an embryo deficient in E2F3 and Rb (E2F3-/-; Rb-/-) develops 
relatively normally even though they die before birth7.  This suggests that the functions of 
Rb and E2F3 balance each other. In an E2F3-/-; Rb-/- double mutant embryo at E13.5 
(when Rb-/- phenotype is most dramatic) the lack of E2F3 completely compensates for the 
lack of Rb in the central nervous system (CNS) and lens.  There were partial rescues in 
the enucleation of red blood cells (RBCs) and Peripheral Nervous System (PNS)7.  Based 
on these observations, E2F3 and Rb play critical roles in embryonic development.  
Recently, Dr Leone’s lab has discovered that the E2F3 gene encodes two distinct 
mRNAs that lead to the synthesis of two E2F3 proteins, E2F3a and E2F3b21.   This is 
very interesting because previously researchers assumed that only one gene product was 
made at the E2F3 locus.  They share homology throughout the protein sequence from 
exon 2 to the C-terminus (fig. 2).  The only difference between the two isoforms is in 
exon 1.  The exon for E2f3a is termed exon 1a and is 122 amino acids long.  Exon 1b 
encodes the first exon for E2f3b and is only six amino acids in length and are different 
from exon 1a21.  Both proteins share the same nuclear localization signal, DNA binding, 
heterodimerization, and pocket protein binding domains; however, E2F3a has a cyclin A 
binding domain in exon 1a21.  The transcription of the two isoforms is regulated by 
distinct promoters21.  In the promoter region of E2f3a there are several E2F binding sites 
as well as a Sp1 sequence and potential Myc binding sites.  On the other hand, the 
promoter region for E2F3b does not contain an E2F or Myc binding site21.  Both gene 
products bind exclusively with Rb21.  In fact, E2F3b is believed to be the principle E2F 
that associates with Rb21.  Furthermore, E2F3b is constitutively expressed throughout the 
cell cycle as well as in quiescent cells.  On the other hand, the expression pattern of 
E2f3a spikes at the G1/S-phase transition21.  E2F3a is considered to be grouped with 
E2F1 and E2F2 as transcription activators; whereas, E2F3b is considered a transcription 
repressor with E2F4, E2F5, and E2F6.   
Materials and Methods 
Establishment of E2f3a knockout 
Cre-loxP gene-targeting techniques were used to generate E2F3a-deficient mice.  
LoxP sites were placed upstream and downstream of exon1a without affecting E2F3b.  
The cell lines were elctroporated and selected for by G418.  Desired ES cell lines were 
verified by Southern blot analysis.  The ES cell lines were then used to create chimeric 
mice and then the chimeric mice were further crossed to Cre transgenic mice for deletion 
of exon1a to generate E2f3a+/- mice.  Effective deletion of the E2F3a gene was verified 
using Southern and Western blots.  The E2f3a+/- animals were bred in a mixed 
background (129/sv X FVB) or backcrossed to a FVB background.  These mice were 
further intercrossed to generate E2f3a-/- mice to study E2f3a function.    
 
Manifestation of embryonic mice  
Rb+/-; E2f3a+/- mice were intercrossed to produce genotypes of interest.  Coitus 
was determined via vaginal plug; the morning after coitus was considered 0.5 days 
postcoitum.  Pregnant females were harvested at 13.5 days postcoitum for histological 
analysis; while 15.5, 16.5, and 17.5 days postcoitum females were harvested to establish 
viability.  Tissue samples were immediately fixed in formalin.  I analyzed three embryos 
from each genotype (four for Rb-/-; E2f3a-/-) that were obtained from different litters.  
Hematoxylin and Eosin (H & E) staining was used to analyze cell morphology.  
Genotypes of mice and embryos were determined by PCR analysis in which three 
primers (primer 1: GCTAGCAGTGCCCTTTTGTC; primer 2: 
TCCAGTGCACTACTCCCTCC; primer 3: CTCCAGACCCCCGATTATTT) were used. 
 BrdU Incorporation and TUNEL Assay      
Pregnant females (13.5 days postcoitum) were injected intraperitoneally with 5’-
bromodeoxyuridine (BrdU) (100 ug/grams of body weight) 2 hours prior to harvesting.  
Desired tissues were fixed in formalin upon harvesting.  Sections (5 um) embedded in 
paraffin were deparffinized, hydrated, treated with Triton X, digested in Proteinase K, 
and denatured in HCl.  Anti-BrdU antibody (DAKO Co. MO-0744) was used to detect 
BrdU incorporation.  Also, an anti-mouse IgG secondary antibody (Vector, MOM Kit 
PK-2200) detected the primary antibody.  For lens tissue, Alexa 594 (rhodamine) was 
used to tag the secondary antibody followed by a 4',6-Diamidino-2-phenylindole (DAPI) 
counter stain.  In the fourth ventricle, placenta, and dorsal ganglia Vectastain Elite ABC 
reagent (Vector) followed by DAB peroxidase (Vector, SC-4100) to develop positive 
signals.  DAB stained slides were counterstained with hematoxylin.  Apoptotic cells were 
determined using a TdT-mediated dUTP nick end-labeling (TUNEL) assay.  The assay 
was performed using the manufacturer’s protocol (Chemican S7101) except that the TdT 
enzyme was incubated at room temperature for 1.5 hours and the Anti-Digoxigenin 
conjugate was incubated at room temperature for 1 hour.  All slides were counterstained 
with hematoxylin.  
 
Determination of Hematopoietic Nucleation 
Blood samples were (4 uL) were spread on slides.  Giemsa stain (Sigma, diluted 
1:20) was used per manufacturer’s protocol to determined nucleation of red blood cells.  
The same embryos were used both for hematopoietic analysis and histochemical analysis.  
 Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblasts (MEFs) of E13.5 embryos were prepared using 
standard methods.  When cells were almost confluent, they were frozen with liquid 
nitrogen in a freezing medium (Dulbecco Minimal Essential Medium with 10% DMSO 
and 25% FBS).  The MEFs were unfrozen using standard protocols for analysis. 
 
Quantification of data  
 To quantify the proliferation and apoptosis data I counted positive-labeled cells 
and then divided the total number of cells.  The quotient was a standardized percentage 
that was easy to compare across genotypes.  About ten areas from each embryo’s 
labyrinth layer of the placenta were counted for comparison.  The post-mitotic zone of 
the fourth ventricle was used to quantify the CNS.  In the PNS several dorsal ganglia in 
different vertebra were counted.  All the cells of the lens fiber, which is dorsal of the 
actual lens, were counted for several sections from each embryo’s eyes.   
Results 
 Earlier studies have shown that the ablation of E2f3 leads to reduced viability and 
health problems in mice19.  With the discovery of two distinct gene products from the 
E2f3 locus, understanding the contribution of each protein is of interest.  E2f3a knockout 
mice were generated by using cre-loxP gene-targeting techniques (Fig. 3a).  Afterwards, 
the successful knockout was confirmed by Southern and Western blot analyses with no 
difference of expression of E2F3b (Fig. 3b & c).  We found that the E2f3a-deficient mice 
were completely viable and appeared with proper Mendelian proportions.  They show no 
defects and have the same livelihood as their wild type counterparts.  They breed 
normally and have the same lifespan as E2f3a+/+ mice.  From these results, E2F3a is not 
needed for neonatal viability.  Furthermore, the E2f3a-deficient mice show no signs of 
congestive heart failure which is a trademark of E2f3-/- mice.  Largely, there are no 
apparent anatomical or histological differences between adult E2f3a-/- mice and E2f3a+/+ 
littermates. 
 MEFs were used to analyze the result of E2f3a-deficiency at the cellular level 
without affecting E2f3b expression.  As expected, E2f3a-/- cells were delayed in entering 
S-phase as compared to wild type MEFs cultured from the same litter (courtesy of Shih-
Yin Tsai).  Because E2F3a is a transcription activator, the loss of it should reduce 
initiation of transcription.  Other experiments have determined the E2F-responsive genes 
that E2F3a induces.  Some of these are cdc6, cyclinE, mcm3, polα, DHFR, and PCNA.  
After serum stimulation the gene expression of these downstream targets in E2f3a-/- 
MEFs is significantly lower than E2f3+/+ MEFs.  The reduction in expression of these 
genes that are required for transcription could be responsible for the delay of S-phase 
entry.   
 Since neonatal viability of E2f3a-deficient mice was established, I next focused 
on embryonic development.  E2f3a+/- mice were intercrossed and mothers were harvested 
at E13.5 to analyze the embryos.  Visually there was no difference between E2f3a-/- mice 
and E2f3a+/+ littermates (Fig. 4).  Further internal analysis reinforced the initial 
observation.  To examine morphology, slide sections of embryos were stained with 
Hematoxylin and Eosin.  The embryo sections showed no difference in cell morphology 
or anatomical proximity (Fig. 4). 
E2f3a and Rb have opposing roles in the Rb/E2f pathway; Rb regulates the 
activities of E2Fs by binding to them.  Loss of Rb results in unregulated E2F activity 
which leads to ectopic S-phase entry and inappropriate apoptosis.  The loss of Rb 
regulation is lethal and results in embryonic death around E14.  Previous studies indicate 
that the loss of certain E2Fs suppresses the developmental defects caused by Rb-
deficiency and even extends embryonic viability up to E17.5.  I was interested in 
determining if E2F3a was responsible for contributing to the phenotype caused by Rb-
deficiency.  Crosses of either Rb+/-; E2f3a+/- or Rb+/-; E2f3a-/- mice with Rb+/-; E2f3a+/- 
were used to achieve Rb-/-; E2f3a-/- embryos.  Notably, these double knockout embryos 
had extended viability up to E17.5 (Table 1).  This shows that E2F3a significantly 
impairs the proper development of Rb-deficient embryos.  No double knockout embryos 
survived to full term.  Possibly, the role of Rb in late embryonic development of certain 
tissues causes the lethality of embryos that lack Rb. 
The increased viability of the embryos suggests that the loss of E2f3a must 
suppress the phenotype of Rb-deficient embryos.  Because E2F3a and Rb oppose each 
other in the respective pathway the loss of E2F3a could rescue ectopic proliferation and 
inappropriate apoptosis arising from Rb-deficiency.  To determine this I examined 
proliferation, apoptosis, and cell morphology of tissues that are affected by Rb-
deficiency.  Examining the development of tissues that express Rb at E13.5, a critical 
time for Rb expression, will give insight into what is occurring in the embryo.  The 
placenta, fourth ventricle of the brain, dorsal ganglia, lens fiber, and red blood cells were 
all analyzed for the rescue capability of the double knockout. 
 Rb-/- embryos show a strong phenotype in the placenta.  Particularly, dysplasia of 
trophoblast cells occurs and they invade the labyrinth layer of the placenta where oxygen 
exchange occurs between the mother and the embryo.  With high levels of proliferation 
and apoptosis, the morphology of the labyrinth layer of the placenta is distorted and 
vascularization is decreased which reduces oxygen exchange.  In Rb-/- embryos, 
phenotypes arising from Rb-deficiency were rescued by the incorporation of a wild type 
placenta for the embryo.  Because E2F3a opposes Rb in cell cycle, I was interested in 
discovering if E2f3a contributed to the phenotype in Rb-deficient placentas.  To 
accomplish this I examined placentas from placentas from Rb+/+; E2f3a+/+, Rb-/-; 
E2f3a+/+, Rb-/-; E2f3a-/-, and Rb+/+; E2f3a-/- embryos.  The embryo sections were H & E 
stained in order to show cell morphology.  Embryos were dissected at E13.5 because that 
is when Rb is critical for development and Rb-/-; E2f3a+/+ embryos usually die after E14.  
As expected the E13.5 Rb-/- embryo’s placentas phenotypes matched previously 
published results7.  Furthermore, E2F3a-/- placentas showed no variation from the wild 
type placentas (Fig. 5a).  In Rb-/-; E2f3a-/- embryos the morphology was restored to the 
wild type phenotype; there were no clusters of trophoblast cells in the labyrinth.  
Furthermore, vascularization appears to be improved over the Rb-deficient embryos 
which should lead to better oxygen exchange.   
 In light of morphology being rescued, other cellular processes might exhibit wild 
type activity also.  Because the loss of Rb results in ectopic S-phase entry and 
inappropriate apoptosis, I tested the same placenta samples for proliferation and 
apoptosis.  To test for proliferation I used BrdU incorporation.  BrdU was injected into 
the pregnant mother two hours before harvesting.  In the wild type placenta an average of 
22.01% of the cells in the labyrinth were in S-phase (Fig. 5b).  In Rb-/-; E2f3a+/+ 
placentas nearly 43% of the cells were in S-phase.  The loss of E2F3a, Rb-/-; E2f3a-/-, 
rescued the proliferation in the placenta, only 19.26% of the cells are in S-phase.  As 
expected, there is no difference between Rb+/+; E2f3a-/- and wild type embryos.  Next, 
inappropriate apoptosis was quantified using TUNEL assays.  The loss of E2F3a 
significantly reduced inappropriate apoptosis in the Rb-deficient embryo; however, a 
complete rescue was not observed (Fig. 5c). 
In previous experiments the loss of E2F3 has shown to completely suppress the 
neurological defects of Rb-deficiency in murine embryos7.  I was interested whether the 
loss of E2F3a would have the same effect.  Using the same embryos from previous 
experiments, I examined both the fourth ventricle of the CNS and the dorsal ganglia from 
the PNS in Rb+/+; E2f3a+/+, Rb-/-; E2f3a+/+, Rb-/-; E2f3a-/-, and Rb+/+ E2f3a-/- embryos at 
E13.5.  Morphologically there was a small detectable difference in the CNS between 
genotypes (Fig. 6a).  However, quantification of the proliferating cells in the post-mitotic 
region of the fourth ventricle showed an Rb-deficient phenotype.  As expected the Rb+/+; 
E2f3a+/+ and Rb+/+; E2f3a-/- embryos had very low levels of proliferation in the post-
mitotic region.  The Rb-/-; E2f3a+/+ embryos had cells proliferating in the post-mitotic 
region (about 7%) as previously characterized (Fig. 6b).  Like in the placenta, the Rb-/-; 
E2f3a-/- embryos showed a complete rescue with virtually no proliferating cells in the 
post-mitotic region.  The dorsal ganglia cells were quantified to compare proliferation 
and apoptosis in the PNS (Fig. 6c).  Like in the CNS, the dorsal ganglia demonstrated 
ectopic proliferation in the Rb-/-; E2f3a+/+ embryo (Fig.7).  Consistent with other tissues, 
the Rb+/+; E2f3a+/+ and Rb+/+; E2f3a-/- embryos resembled each other in regards to S-
phase entry of the cells.  The loss of E2f3a only partially rescues ectopic proliferation by 
about 70% (Fig. 7b).  Apoptosis in the nervous system was also measured by TUNEL 
assays.  The fourth ventricle showed a complete rescue.  On the other hand, the dorsal 
ganglia only showed a reduction in cells that stained positive for apoptosis (Fig. 7c). 
In the lens proliferation and apoptosis were also measured.  I was interested in 
quantifying the post-mitotic region known as the lens fiber which is on the dorsal side of 
the actual lens.  The morphology of the lens in the double knockout embryo is severely 
distorted (Fig. 8).  The morphology of the Rb-/-; E2f3a-/- embryos was between the wild 
type and Rb+/+; E2f3a-/- embryos on the basis of cells present in the lens fiber tissue 
samples.  The Rb+/+; E2f3a+/+ and Rb+/+; E2f3a-/- embryos contained a little less than 100 
cells per tissue section of the lens fiber and the Rb+/+; E2f3a-/- embryos contained around 
265 cells per tissue section.  Interestingly, there were about 200 cells per tissue sample in 
the Rb-/-; E2f3a-/- embryos.  Quantifying S-phase entry gave insight into this observation.  
In the lens fiber tissue, the loss of E2F3a reduces ectopic S-phase entry of Rb+/+; E2f3a-/- 
embryos by 45% (Fig. 9a).  Furthermore, apoptosis was only reduced slightly (Fig. 9b). 
Defects in erythroid development have been implicated in causing the Rb-/- 
embryonic lethality around E14.  Our lab showed that replacing an Rb-deficient placenta 
in with a wild type placenta in an Rb-/- embryo will extend viability, but will not 
overcome the erythropoiesis defect13.  In Rb-/- embryos red blood cells (RBCs) do not 
enucleate properly and are ineffective at carrying oxygen13.  Previous experiments 
showed that the loss of E2F3 only partially rescued the enucleation defect in Rb-deficient 
mice7.  I wanted to discern if the loss of E2F3a could also reduce the lack of enucleation.  
By Giemsa staining blood samples of harvested Rb+/+; E2f3a+/+, Rb-/-; E2f3a+/+, Rb-/-; 
E2f3a-/-, and Rb+/+; E2f3a-/- embryos I could quantify if the loss of E2F3a could cause 
more RBCs in Rb-deficient embryos to properly enucleate (Fig 10a).  I discovered that 
there was no difference in the percentage of enucleated cells in Rb+/+; E2f3a-/- and Rb-/-; 
E2f3a-/- embryos (T-test:  p>0.1).  As seen throughout these experiments, there was no 
detectable difference between enucleated RBCs in Rb+/+; E2f3a+/+ and Rb+/+; E2f3a-/- 
embryos (Fig. 10b).  Extended viability did not result from rescued erythroid processes. 
Discussion 
 The explosion of recent knowledge regarding the Rb/E2F pathway has expanded 
the roles of the proteins involved and has increased the understanding how cells are 
complexly regulated.  Previous experiments have shown that Rb and E2F3 are both 
necessary for viability.  E2F3 has shown to be a major contributor to the pathway with 
unique functions.  Without E2F3 MEFs do not divide as quickly as wild type cells.   Also, 
loss of E2F3 up regulates p19ARF expression and E2F3 is required for proper 
centrosome division22.  The discovery of to E2F3 gene products, E2F3a and E2F3b, has 
prompted many questions about the functional specificity of each protein.  Fully 
understanding the pathway relies on elucidating the individual functions of each protein 
and determining redundancy effects.   
 Unlike E2F3-deficient mice, E2F3a-deficient mice are fully viable and exhibit 
normal livelihoods and breeding capabilities.  Whether E2F3b is required for viability or 
if only a component of E2F3 (be it E2F3a or E2F3b) is not known at this time.  
Experiments with E2F3b-deficient mice will help answer this question.  Determining 
what E2F3 activities E2F3a is responsible for is of interest of cell biology and cancer 
research.  Loss of E2F3 has shown to rescue most of the phenotypes caused by Rb-
deficiency as well as extend the life of the embryos from E14 up to E17.  Importantly, my 
study determined that losing just E2F3a has the most of the same rescue capability of 
losing all of the E2F3 protein.  E2F3a-/-; Rb-/- mice show a complete rescued phenotype 
in the placenta and CNS.  Furthermore, there is a partial rescue in the PNS and the lens 
fiber.  However, there is no rescue of the erythropoietic defects caused by Rb-deficiency.  
These findings compared to earlier studies that focused on losing all of E2F3 suggest that 
E2f3a and E2F3b act differently in different tissues.  They may be expressed in different 
amounts in specific tissues or may also have the ability to mimic each others function.  
Further study of E2F3b will fully answer this question.  These studies show that E2F3a is 
the major contributor of the E2F3 gene products for proliferation and apoptosis 
regulation.  This is not to say that E2F3b does not have any of this ability also, although 
E2F3b may act in different tissues than E2F3a.   
 The complete rescue of the placenta is an interesting development.  Our lab 
previously showed that replacing an Rb-deficient placenta with a wild type placenta will 
extend the viability of Rb-/- embryos13.  Interestingly the loss of E2F3a extended the lives 
of these embryos also without rescuing any of the erythropoietic defects.  This 
strengthens the argument that Rb-/- embryos die at E14 because of placenta defects 
instead of erythropoietic defects.  Based on prior experiments, the rescue of the placenta 
caused by the loss of E2f3a in Rb-deficient embryos could be the reason that the embryos 
had extended viabilities up to E17.5. 
 One of the most interesting characteristics of the Rb/E2F pathway is the 
regulation of apoptosis.  Two different models have been proposed for the inappropriate 
apoptosis resulting from Rb-deficiency.  First, the loss of Rb triggers p53-dependent 
apoptosis.  The second model claims that a high concentration of free E2F can trigger 
apoptosis also through both p53-dependent and p53-independent mechanisms.  This may 
be a method to safeguard against unwanted proliferation and ultimately cancer.  My data 
concerning apoptosis was striking in that the rescue of apoptosis varied from a complete 
rescue in some tissues and barely any rescue in other tissues.  Rb-/-; E2F3a+/+ embryos 
are expected to have a high level of apoptosis because of the loss of Rb and the ability to 
control apoptosis.  However, the variation in Rb-/-; E2F3a-/- embryonic apoptosis in 
tissues is shocking.  My data supports that high levels of free E2F can cause apoptosis.  
By losing E2F3a in the Rb-deficient embryo the levels of free E2F are reduced, 
especially if E2F3a is expressed highly in these tissues in wild type embryos.  The 
difference in apoptosis frequency in other tissues may be a result of high E2F3b 
expression or low expression of E2F3a in that tissue in wild type embryos.  One problem 
with this model must be worked out.  Experiments need to determine if the loss of E2F3a 
in specific tissue up regulates expression of other E2Fs in that tissue.   
 E2F3a is characterized as a transcription activator.  MEFs that lack E2F3a are 
slow in initiated replication after serum starvation.  My results show that losing E2F3a in 
the Rb-deficient embryo reduces proliferation.  These combined results suggest that 
E2F3a has oncogenic ability.  E2F3a promotes transcription; without regulation from Rb 
ectopic proliferation happens because of the unregulation of the activator E2Fs.  Further 
experiments need to be done to determine to what extent E2F3a has oncogenic ability; to 
study this, E2F3a could be over expressed in mice to see whether tumor formation 
results. 
 Rb inactivation occurs in most if not all cancers.  Loss of Rb in cancer leads to 
deleterious phenotypes; there is no longer any regulation of proliferation, apoptosis, and 
the cell cycle.  By losing Rb the Rb/E2F pathway loses regulation and the activator E2Fs 
are able to make cells proliferate ectopically.  Study of this pathway in cancer has 
produced many valuable results.  Simultaneously losing an antagonist of Rb can lessen 
the phenotypical consequences of Rb-deficiency and can lead to improved viability by 
suppressing tumor formation.  For instance Rb+/-; E2F3-/- mice have extended viability 
and suppress pituitary tumors in comparison to Rb+/- cancer-prone mice.  My results 
show that the loss of E2F3a mitigates the effects of Rb-deficiency in embryos.  Judging 
by these results, the loss of E2F3a may also suppress tumor formation in Rb+/- mice.  
Currently, I am conducting a tumor study to test for this hypothesis. 
 The E2Fs play an interesting role in cancer.  There purpose is to initiate the G1/S-
phase transition.  Deregulation of the activator E2Fs will lead to ectopic proliferation 
which is a trademark of cancer.  Previous experiments have shown both redundant and 
unique functions among the E2F family.  Some of the E2Fs have a wide array of 
functions.  For instance, E2F3 has proven to be the most unique functions.  There are 
binding sites for the Myc oncogene on the promoter for E2F3.  During a cancerous state, 
E2F3 will be up regulated by increased Myc expression.  An increase in E2F3 expression 
will lead to ectopic proliferation which will promote tumor formation.  Also, E2F3 has 
been shown to regulate centrosome formation in dividing cells.  Cells that lack E2F3 
have abnormal numbers of centrosomes and exhibit aneuploidy.  The resultant abnormal 
cells are irregular and have been shown to lead to increased metastasis.  Completely 
understanding the role of E2F3a will give further insight into the genetics behind cancer.  
Knocking out E2F3a may be a prime choice to reduce cancer phenotypes associated with 
E2F3.  E2f3a has a Myc binding site at the promoter while E2f3b does not.  Ablation of 
the E2F3a gene may not increase proliferation in the presence of Myc up regulation, 
because Myc cannot promote transcription of the protein.  Furthermore, the presence of 
E2F3b may be enough to sustain proper centrosome formation. 
 Controlling E2F function will be paramount for cancer therapeutics in the future.  
If ectopic proliferation is reduced then tumor growth and ultimately metastasis can be 
delayed.  The various E2Fs all have shared and unique functions.  They can exhibit both 
tumor suppressor and oncogene properties.  Understanding the key relationships and 
activities of E2F proteins is vital in understanding and harnessing cancer.  Ablation of an 
E2F may have either positive or negative effects in cancer suppression.  Furthermore, the 
actual function of an E2F may vary between tissues.  Considerable research into 
understanding E2F functions very well may lead to devising cancer therapies in the 
future. 
Acknowledgements 
 I first would like to thank Gustavo Leone for giving me the opportunity and 
funding to pursue research in his laboratory.  Jean-Leon Chong is not only a great mentor 
but a friend.  Both Gustavo and Leon were critical in developing the project and assisting 
with the execution of the experiments.  This experiment would not be possible if Rene 
Oparvsky did not knock out the E2f3a gene.  I would also like to thank Shih-Yin Tsai for 
MEF data.  Much appreciation and thanks goes out to Anthony Trimboli, Lizhao Wu, 
Pamela Wenzel, and Hui Wang for their patience and assistance in helping me with 
questions.  Finally, I would like to thank my friends and family.  You have been great in 
supporting me through this research project. 
References  
1. Nevins, JR.  The Rb/E2F Pathway and Cancer.  Hum. Mol. Genet.  10, 699-703 
(2001). 
2. Friend, S.H., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, 
D.M., and Dryja, T.P. A human DNA segment with properties of the gene that 
predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646. (1986). 
3. DiCiommo, D., Gallie, B. L., and Bremner, R.  Retinoblastoma:  the disease, gene 
and protein provide critical leads to understanding cancer.  Cancer Biology.  10, 
255-269 (2000). 
4. de Sutter, E., Havers, W., Hopping W., Zeller G., Alberti W.  The prognosis of 
retinoblastoma in terms of survival.  A computer assisted study.  Part II.  
Opthalmic Paediatr Genet.  8, 85-88 (1987) 
5. Weinberg, R.A.  The retinoblastoma protein and cell cycle control.  Cell.  81, 
323-330 (1995). 
6. Zhang, H.S., Gavin, M., Dahiya, A., Postigo, A.A., Ma, D., Luo, R.X., Harbour, 
J.W., and Dean, D.C.  Exit from G1 and S phase of the cell cycle is regulated by 
repressor complexes containing HDAC–Rb–hSWI/SNF and Rb–hSWI/SNF. Cell 
101: 79–89 (2000). 
7. Ziebold, U. et al.  E2F3 contributes both to the inappropriate proliferation and to 
the apoptosis arising in Rb mutant embryos.  Genes and Dev.  15, 386-391 
(2000).  
8. Harbour, J. W. and Dean, D. C.  The Rb/E2F pathway:  expanding roles and 
emerging paradigms.  Genes and Development.  14, 2393-2409 (2000). 
9. Hu, N., A. Gutsmann, D. C. Herbert, A. Bradley, W. H. Lee, and E. Y. Lee. 
Heterozygous Rb-1 delta 20/_ mice are predisposed to tumors of the 
pituitary gland with a nearly complete penetrance. Oncogene 9:1021–1027. 
(1994). 
10. Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in 
neurogenesis and haematopoiesis. Nature 359, 288–294 (1992). 
11. Clarke, A. R. et al. Requirement for a functional Rb-1 gene in murine 
development. Nature.   359, 328–330 (1992). 
12. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature.   359, 295–300 
(1992). 
13.  Wu, L., de Bruin, A., Saavedra, H. I., Starovic, M., Trimboli, A., Yang, Y., 
Opavska, J., Wilson, P., Thompson, J. C., Ostrowski, M. C., Leone, G. W.  Extra-
embryonic function of Rb is essential for embryonic development and viability.  
Nature.  421, 942–947 (2003). 
14. Ziebold, U. et al.  E2F3 loss has opposing effects on different pRB-deficient 
tumors, resulting in suppression of pituitary tumors but metastasis of medullary 
thyroid carcinomas.  Mol. and Cellular Bio.  2003, 6542-6552 (2003). 
15. Helin, K., C. L. Wu, A. R. Fattaey, J. A. Lees, B. D. Dynlacht, C. Ngwu, and E. 
Harlow. 1993. Heterodimerization of the transcription factors E2F-1 and DP-1 
leads to cooperative trans-activation. Genes Dev. 7:1850–1861. 
16. Cloud, J.E., Rogers, C., Reza, T.L., Ziebold, U., Stone, J.R., Picard, M.H., 2001). 
a Caron, A.M., Bronson, R.T., and Lees, J.A. Mutant mouse models reveal the 
relative roles of E2F1 and E2F3 in vivo. Mol  Cell Biol 22, 2663–2672 (2002). 
17. Cam, H and Dynlacht.  Emerging roles for E2F:  Beyond the G1/S transition and 
DNA replication.  Cancer Cell.  3, 311-316 (2003). 
18. Ma, D, Zhou, P, and Harbour, J. W.  Distinct mechanisms for regulating the 
tumor suppressor and antiapoptotic function of Rb.  J of Bio Chem.  21, 19358-
19366 (2003). 
19. Humbert, P.O., Verona, R., Trimarchi, J.M., Rogers, C., Dandapani,S., and Lees, 
J.A. 2000. E2f3 is critical for normal cellular proliferation. Genes & Dev. 14: 
690–703. 
20. Aslanian, A, Iaquinta, P. J., Verona, R, Lees, J. A.  Repression of the Arf tumor 
suppressor be E2F3 is required for normal cell cycle kinetics.  Genes and 
Development.  18, 1413-1422 (2004). 
21. Leone, G., Nuckolls, F., Ishida, S., Adams, M., Sears, R., Jakoi, L., Miron A., and 
Nevins, J.R. Identification of a novel E2F3 product suggests a mechanism for 
determining specificity of repression by Rb proteins. Mol Cell Biol. 20, 3626–
3632 (2002). 
22. Saavedra, H. I., Maiti, B., Timmers, C., Altura, R., Tokuyama, Y., Fukasawa, K., 
Leone, G.  Inactivation of E2F3 results in centrosome amplification.  Cancer Cell.   



































of S phase 























. . . . . . . 
















. . . . . . . 


















































































rotein sequences for E
2F3a and E2F3b.  Exon
1a is 122 am
ino acids long w
hile exon
1b is 6 am
ino acids long.  
E
xons






Tk-Neo 1a 721b Targeting Vector
721b Targeted locus
1a 721b












+/+      -/-
Generation of E2f3a-deficient mice.  A, genomic structure of the E2f3a locus.  
Exon of interested is exon 1a.  Three loxp sites and Cre-mediated deletion 
removes the exon.  The southern probe is upstream of exon 1a.  B, Southern 
blot analysis of DNA from embryos with the indicated genotypes. C, Western 
blot analysis showing deletion of E2F3a protein and unaffected expression of 
E2F3b protein
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BrdU positive cell graph for lens fiber






































A, Giemsa stain of RBCs.  B, Nucleated RBC data
